Maurice Zauderer
Overview
Explore the profile of Maurice Zauderer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feigin A, Evans E, Fisher T, Zauderer M
Expert Opin Investig Drugs
. 2025 Feb;
:1-11.
PMID: 40007468
Introduction: Huntington's Disease (HD) is a progressive fatal neurodegenerative disease with an unmet need for disease-modifying therapies. Neuroinflammation, particularly astrogliosis, plays a crucial role in the pathogenesis of HD and...
2.
Greengard E, Williams R, Moriarity B, Liu X, Minard C, Reid J, et al.
Pediatr Blood Cancer
. 2024 Mar;
71(6):e30938.
PMID: 38520670
Purpose: Pepinemab, a humanized IgG4 monoclonal antibody, targets the SEMA4D (CD100) antigen to inhibit binding to its high-affinity receptors (plexin B1/PLXNB1, plexin B2/PLXNB2) and low-affinity receptor (CD72). SEMA4D blockade leads...
3.
Smith E, Balch L, Scrivens M, Shi S, Wang W, Harvey C, et al.
MAbs
. 2023 Aug;
15(1):2249947.
PMID: 37635331
Antibody discovery against complex antigens is limited by the availability of a reproducible pure source of concentrated properly folded antigen. We have developed a technology to enable direct incorporation of...
4.
Klenk C, Scrivens M, Niederer A, Shi S, Mueller L, Gersz E, et al.
Nat Commun
. 2023 Mar;
14(1):1770.
PMID: 36997531
Directed evolution in bacterial or yeast display systems has been successfully used to improve stability and expression of G protein-coupled receptors for structural and biophysical studies. Yet, several receptors cannot...
5.
6.
Feigin A, Evans E, Fisher T, Leonard J, Smith E, Reader A, et al.
Nat Med
. 2022 Oct;
30(2):606.
PMID: 36195687
No abstract available.
7.
Feigin A, Evans E, Fisher T, Leonard J, Smith E, Reader A, et al.
Nat Med
. 2022 Aug;
28(10):2183-2193.
PMID: 35941373
SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase 2 study (no. NCT02481674) established to evaluate pepinemab, a semaphorin 4D (SEMA4D)-blocking antibody, for treatment of Huntington's disease (HD). The trial enrolled...
8.
Evans E, Mishra V, Mallow C, Gersz E, Balch L, Howell A, et al.
J Neuroinflammation
. 2022 Aug;
19(1):200.
PMID: 35933420
Background: The close interaction and interdependence of astrocytes and neurons allows for the possibility that astrocyte dysfunction contributes to and amplifies neurodegenerative pathology. Molecular pathways that trigger reactive astrocytes may...
9.
Tabrizi S, Schobel S, Gantman E, Mansbach A, Borowsky B, Konstantinova P, et al.
Lancet Neurol
. 2022 Jun;
21(7):632-644.
PMID: 35716693
The current research paradigm for Huntington's disease is based on participants with overt clinical phenotypes and does not address its pathophysiology nor the biomarker changes that can precede by decades...
10.
Mao Y, Evans E, Mishra V, Balch L, Eberhardt A, Zauderer M, et al.
Int J Mol Sci
. 2021 Sep;
22(17).
PMID: 34502373
Rett syndrome is a neurodevelopmental disorder caused by mutations of the methyl-CpG binding protein 2 gene. Abnormal physiological functions of glial cells contribute to pathogenesis of Rett syndrome. Semaphorin 4D...